Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (442) 442
trimetazidine - therapeutic use (420) 420
trimetazidine (389) 389
male (320) 320
vasodilator agents - therapeutic use (290) 290
female (200) 200
middle aged (195) 195
animals (192) 192
index medicus (175) 175
cardiac & cardiovascular systems (169) 169
pharmacology & pharmacy (162) 162
trimetazidine - pharmacology (146) 146
aged (137) 137
rats (113) 113
treatment outcome (108) 108
angina pectoris - drug therapy (88) 88
double-blind method (79) 79
adult (78) 78
vasodilator agents - pharmacology (77) 77
trimetazidine - administration & dosage (75) 75
myocardial ischemia - drug therapy (74) 74
myocardium - metabolism (74) 74
double-blind (72) 72
metabolism (72) 72
cardiology (68) 68
ischemia (68) 68
stable angina (68) 68
fatty-acid oxidation (64) 64
heart failure (64) 64
angina pectoris (61) 61
drug therapy, combination (61) 61
heart failure - drug therapy (53) 53
ranolazine (51) 51
heart (50) 50
oxidative stress (50) 50
rats, wistar (50) 50
vasodilator agents - administration & dosage (50) 50
medicine & public health (48) 48
analysis (47) 47
care and treatment (43) 43
piperazines - therapeutic use (43) 43
reperfusion (43) 43
coronary-artery-disease (42) 42
drug therapy (42) 42
medicine, general & internal (42) 42
disease models, animal (41) 41
myocardial infarction - drug therapy (41) 41
acute myocardial-infarction (39) 39
electrocardiography (37) 37
exercise test (37) 37
fatty acids - metabolism (37) 37
time factors (37) 37
echocardiography (36) 36
glucose-oxidation (36) 36
left-ventricular function (36) 36
mortality (36) 36
myocardial ischemia - physiopathology (36) 36
angina (35) 35
ventricular function, left - drug effects (35) 35
heart failure - metabolism (34) 34
prospective studies (34) 34
fatty acids (33) 33
research (33) 33
cardiovascular agents - therapeutic use (32) 32
diabetes (32) 32
ischemic cardiomyopathy (32) 32
myocardial ischemia (32) 32
myocardial ischemia - metabolism (32) 32
apoptosis (31) 31
energy metabolism - drug effects (31) 31
follow-up studies (30) 30
glucose (30) 30
heart - drug effects (30) 30
heart diseases (30) 30
heart-failure (30) 30
rats, sprague-dawley (30) 30
cardiac patients (29) 29
cardiomyopathy (29) 29
coronary disease - drug therapy (29) 29
disease (29) 29
injury (29) 29
trimetazidine - adverse effects (29) 29
medicine, research & experimental (28) 28
rat-heart (28) 28
cardiovascular (27) 27
coronary heart disease (27) 27
glucose - metabolism (27) 27
adrenergic beta-antagonists - therapeutic use (26) 26
heart attacks (26) 26
dose-response relationship, drug (25) 25
efficacy (25) 25
ischemia-reperfusion (25) 25
ischemia-reperfusion injury (25) 25
myocardial-infarction (25) 25
physiological aspects (25) 25
reperfusion injury (25) 25
rodents (25) 25
chronic disease (24) 24
dosage and administration (24) 24
energy-metabolism (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (549) 549
Russian (67) 67
French (31) 31
Chinese (13) 13
Spanish (7) 7
Polish (6) 6
Czech (4) 4
Hungarian (4) 4
Italian (4) 4
Croatian (1) 1
Japanese (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: Exploiting Randle's cycle
by Fang, Yong-Hu and Piao, Lin and Hong, Zhigang and Toth, Peter T and Marsboom, Glenn and Bache-Wiig, Peter and Rehman, Jalees and Archer, Stephen L
Journal of Molecular Medicine, ISSN 0946-2716, 01/2012, Volume 90, Issue 1, pp. 31 - 43
Right ventricular hypertrophy (RVH) and RV failure are major determinants of prognosis in pulmonary hypertension and congenital heart disease. In RVH, there is... 
QTc interval | Myocardial fibrosis | Monophasic action potential duration | Pulmonic stenosis | Right heart failure | MEDICINE, RESEARCH & EXPERIMENTAL | STABLE ANGINA | GLUCOSE-OXIDATION | MITOCHONDRIAL-FUNCTION | ISCHEMIA | CARDIAC-MUSCLE | TRIMETAZIDINE | RAT HEARTS | METABOLISM | RANOLAZINE | GENETICS & HEREDITY | SUPEROXIDE PRODUCTION | Vasodilator Agents - therapeutic use | Glucose Transporter Type 1 - metabolism | Male | Hypertrophy, Right Ventricular - drug therapy | Ranolazine | Glycogen - metabolism | Acetanilides - therapeutic use | Trimetazidine - pharmacology | Ventricular Function, Right - drug effects | Hexokinase - genetics | Fatty Acids - metabolism | Hypertrophy, Right Ventricular - metabolism | Trimetazidine - therapeutic use | Acetanilides - pharmacology | Vasodilator Agents - pharmacology | Oxidation-Reduction | Enzyme Inhibitors - pharmacology | Rats | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Piperazines - pharmacology | Rats, Sprague-Dawley | Animals | Myocytes, Cardiac - drug effects | Glucose Transporter Type 1 - genetics | Glycolysis | Myocytes, Cardiac - metabolism | Hexokinase - metabolism | Physiological aspects | Biological oxidation (Metabolism) | Research | Heart enlargement
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Metabolic manipulation in ischaemic heart disease, a novel approach to treatment
by Lee, Leong and Horowitz, John and Frenneaux, Michael
European Heart Journal, ISSN 0195-668X, 04/2004, Volume 25, Issue 8, pp. 634 - 641
Antianginal drugs that exert their anti-ischaemic effects primarily by altering myocardial metabolism have recently attracted attention. They have the... 
Angina | Metabolism | Perhexiline | Etomoxir | Trimetazidine | Ranolazine | CARDIAC & CARDIOVASCULAR SYSTEMS | PERHEXILINE-MALEATE | FATTY-ACID OXIDATION | CARNITINE PALMITOYLTRANSFERASE-1 | STABLE ANGINA-PECTORIS | ACUTE MYOCARDIAL-INFARCTION | DOUBLE-BLIND | COENZYME-A THIOLASE | RAT-HEART | GLUCOSE-INSULIN-POTASSIUM | CORONARY-ARTERY-DISEASE | Hypoglycemic Agents - therapeutic use | Epoxy Compounds - therapeutic use | Myocardial Ischemia - metabolism | Trimetazidine - therapeutic use | Humans | Angina Pectoris - drug therapy | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Myocardial Ischemia - drug therapy | Cardiovascular Agents - therapeutic use | Myocardium - metabolism | Potassium - therapeutic use | Glucose - therapeutic use | Perhexiline - therapeutic use | Drug Therapy, Combination | Acetanilides | Insulin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Metabolic support for the heart: complementary therapy for heart failure?
by Heggermont, Ward A and Papageorgiou, Anna-Pia and Heymans, Stephane and van Bilsen, Marc
European journal of heart failure, ISSN 1388-9842, 12/2016, Volume 18, Issue 12, pp. 1420 - 1429
The failing heart has an increased metabolic demand and at the same time suffers from impaired energy efficiency, which is a detrimental combination.... 
Heart failure | Energy starvation | Cardiac metabolism | Metabolic therapy | Foetal switch | OMECAMTIV-MECARBIL | CARDIAC & CARDIOVASCULAR SYSTEMS | CLINICAL-TRIAL | MYOCARDIAL-FUNCTION | CARDIAC MYOSIN ACTIVATOR | PRESERVED EJECTION FRACTION | FETAL GENE PROGRAM | DIASTOLIC DYSFUNCTION | FATTY-ACID OXIDATION | FAILING HEART | DOUBLE-BLIND | Epoxy Compounds - therapeutic use | Trimetazidine - therapeutic use | Oxidation-Reduction | Ranolazine - therapeutic use | Humans | Heart Failure - physiopathology | Heart Failure - metabolism | Dichloroacetic Acid - therapeutic use | Enzyme Inhibitors - therapeutic use | Heart Failure - drug therapy | Stroke Volume | Cardiovascular Agents - therapeutic use | Carnitine O-Palmitoyltransferase - antagonists & inhibitors | Energy Metabolism | Myocardium - metabolism | Carnitine - therapeutic use | Glucose - metabolism | Myocytes, Cardiac - metabolism | Acetyl-CoA C-Acyltransferase - antagonists & inhibitors | Carnitine - analogs & derivatives | Perhexiline - therapeutic use | Fatty Acids - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Additional use of trimetazidine in patients with chronic heart failure: A meta-analysis
by Zhang, Lei and Lu, Yizhou and Jiang, Hong and Zhang, Liming and Sun, Aijun and Zou, Yunzeng and Ge, Junbo
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2012, Volume 59, Issue 10, pp. 913 - 922
Objectives: The aim of this meta-analysis was to evaluate the effects of additional trimetazidine (TMZ) treatment on patients with chronic heart failure (CHF).... 
meta-analysis | cardiac function | chronic heart failure | trimetazidine | prognosis | Trimetazidine - therapeutic use | Prognosis | Vasodilator Agents - therapeutic use | Humans | Heart Failure - physiopathology | Trimetazidine - administration & dosage | Vasodilator Agents - administration & dosage | Ventricular Remodeling - drug effects | Disease Progression | Heart Failure - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Energy remodeling, mitochondrial disorder and heart failure
by Wang, Peng and Xu, Lei and Sun, Aijun
Current Pharmaceutical Design, ISSN 1381-6128, 09/2016, Volume 22, Issue 31, pp. 4823 - 4829
Heart failure (HF) is a major global problem in public health with no curative treatment currently available. Energy remodeling is one of the features in HF,... 
Heart failure | Energy metabolism | Mitochondrial disorder | heart failure | PRESSURE-OVERLOAD | OXIDATIVE STRESS | ACTIVATED PROTEIN-KINASE | MYOCARDIAL-INFARCTION | mitochondrial disorder | EXERCISE CAPACITY | METABOLIC THERAPY | CYTOCHROME-C | FAILING HEART | CARDIAC-HYPERTROPHY | THERAPEUTIC TARGET | PHARMACOLOGY & PHARMACY | Mitochondrial Diseases - drug therapy | Trimetazidine - therapeutic use | Metformin - therapeutic use | Aminoimidazole Carboxamide - therapeutic use | Humans | Mitochondrial Diseases - metabolism | Heart Failure - metabolism | Heart Failure - drug therapy | Ribonucleotides - therapeutic use | Thiazolidinediones - therapeutic use | Animals | Aminoimidazole Carboxamide - analogs & derivatives | Energy Metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Journal Article
Details down arrow
6. Full Text Inhibition of Cancer Cell Proliferation by PPARγ Is Mediated by a Metabolic Switch that Increases Reactive Oxygen Species Levels
by Srivastava, Nishi and Kollipara, Rahul K and Singh, Dinesh K and Sudderth, Jessica and Hu, Zeping and Nguyen, Hien and Wang, Shan and Humphries, Caroline G and Carstens, Ryan and Huffman, Kenneth E and DeBerardinis, Ralph J and Kittler, Ralf
Cell Metabolism, ISSN 1550-4131, 10/2014, Volume 20, Issue 4, pp. 650 - 661
The nuclear receptor peroxisome-proliferation-activated receptor gamma (PPARγ), a transcriptional master regulator of glucose and lipid metabolism, inhibits... 
LUNG-CANCER | ACTIVATED RECEPTOR-GAMMA | KIDNEY-TYPE GLUTAMINASE | RETINOBLASTOMA PROTEIN | PYRUVATE-KINASE | MECHANISM | DNA | BIOLOGY | GROWTH | ENDOCRINOLOGY & METABOLISM | EXPRESSION | CELL BIOLOGY | Neoplasms - metabolism | Protein Kinases - metabolism | Reactive Oxygen Species - metabolism | Humans | Transplantation, Heterologous | Antineoplastic Agents - therapeutic use | PPAR gamma - metabolism | Protein Interaction Maps | Thiazolidinediones - therapeutic use | Lipid Peroxidation - drug effects | Trimetazidine - pharmacology | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Thiazolidinediones - pharmacology | Fatty Acids - metabolism | Trimetazidine - therapeutic use | Fatty Acids - chemistry | Retinoblastoma Protein - metabolism | Mice, SCID | Neoplasms - drug therapy | Animals | PPAR gamma - antagonists & inhibitors | Cell Cycle Checkpoints - drug effects | PPAR gamma - agonists | Cell Line, Tumor | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Trimetazidine: a meta-analysis of randomised controlled trials in heart failure
by Gao, Dengfeng and Ning, Ning and Niu, Xiaolin and Hao, Guanghua and Meng, Zhe
Heart, ISSN 1355-6037, 02/2011, Volume 97, Issue 4, pp. 278 - 286
ObjectiveTo explore whether trimetazidine could improve symptoms, cardiac functions and clinical outcomes in patients with heart failure (HF).MethodsA... 
DIABETIC-PATIENTS | CARDIAC & CARDIOVASCULAR SYSTEMS | ISCHEMIC CARDIOMYOPATHY | MANAGEMENT | OPTIMAL SEARCH STRATEGIES | QUALITY-OF-LIFE | SYSTOLIC FUNCTION | DYSFUNCTION | ELDERLY-PATIENTS | MODULATION | LEFT-VENTRICULAR FUNCTION | Trimetazidine - therapeutic use | Vasodilator Agents - therapeutic use | Humans | Heart Failure - physiopathology | Stroke Volume - drug effects | Treatment Outcome | Enzyme Inhibitors - therapeutic use | Heart Failure - drug therapy | Randomized Controlled Trials as Topic | Ventricular Remodeling | Exercise Tolerance | Adult | Acetyl-CoA C-Acyltransferase - antagonists & inhibitors | Chronic Disease | Heart failure | Usage | Analysis | Patient outcomes | Drug therapy | Health aspects | Cardiovascular agents | Heart attacks | Statistical analysis | Mortality | Clinical trials | Metabolism | Patients | Data bases | Meta-analysis | Studies | Validity | Quality | Classification | Oxidation | Cardiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Update on pulmonary arterial hypertension pharmacotherapy
by Velayati, Arash and Valerio, Marcos G and Shen, Michael and Tariq, Sohaib and Lanier, Gregg M and Aronow, Wilbert S
Postgraduate Medicine, ISSN 0032-5481, 07/2016, Volume 128, Issue 5, pp. 460 - 473
Pulmonary artery hypertension (PAH) refers to several subgroups of disease in which the mean pulmonary artery pressure (mPAP) is elevated to more than 25 mm... 
nifedipine | selexipag | diltiazem | nitric oxide | Imatinib | tadalafil | iloprost | prostacyclin | epoprostenol | ambrisentan | beraprost | amlodipine sildenafil | trimetazidine | Pulmonary hypertension | vardenafil riociguat | PDE-5i | dichloroacetate | bosentan | macitentan | PAH | guanylate cyclase | cyclic AMP | ranolazine | CTEPH | RHO-KINASE INHIBITOR | RANDOMIZED CONTROLLED-TRIAL | CONTROLLED CLINICAL-TRIAL | ADD-ON THERAPY | MEDICINE, GENERAL & INTERNAL | RIGHT-VENTRICULAR FUNCTION | INHALED ILOPROST | AMBRISENTAN THERAPY | DOUBLE-BLIND | PLACEBO-CONTROLLED TRIAL | LONG-TERM TREATMENT | Pyrazoles - therapeutic use | Soluble Guanylyl Cyclase - metabolism | Humans | Calcium Channel Blockers - therapeutic use | Pulmonary Artery | Dichloroacetic Acid - therapeutic use | rho-Associated Kinases - antagonists & inhibitors | Epoprostenol - therapeutic use | Receptors, Epoprostenol - antagonists & inhibitors | Epoprostenol - analogs & derivatives | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Registries | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Drug Therapy, Combination | Endothelin Receptor Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Metabolic abnormalities of the heart in type II diabetes
by Amaral, Nelson and Okonko, Darlington O
Diabetes & Vascular Disease Research, ISSN 1479-1641, 7/2015, Volume 12, Issue 4, pp. 239 - 248
Type 2 diabetes mellitus escalates the risk of heart failure partly via its ability to induce a cardiomyopathic state that is independent of coronary artery... 
Metabolism | diabetes | energetics | SUBSTRATE UTILIZATION | PEROXISOME PROLIFERATOR | MITOCHONDRIAL METABOLISM | CARDIAC DYSFUNCTION | MYOCARDIAL-METABOLISM | DIASTOLIC DYSFUNCTION | SKELETAL-MUSCLE | FREE FATTY-ACIDS | ADVANCED GLYCATION ENDPRODUCTS | ENDOCRINOLOGY & METABOLISM | PERIPHERAL VASCULAR DISEASE | RAT-HEART | Trimetazidine - therapeutic use | Diabetic Cardiomyopathies - metabolism | Mitochondria, Heart - metabolism | Diabetic Cardiomyopathies - drug therapy | Diabetic Cardiomyopathies - etiology | Oxidative Stress | Ranolazine - therapeutic use | Humans | Ubiquinone - analogs & derivatives | Organophosphorus Compounds - therapeutic use | Oxidative Phosphorylation | Diabetes Mellitus, Type 2 - metabolism | Cardiovascular Agents - therapeutic use | Antioxidants - therapeutic use | Energy Metabolism | Myocardium - metabolism | Glucose - metabolism | Ubiquinone - therapeutic use | Perhexiline - therapeutic use | Fatty Acids - metabolism | Diabetes Mellitus, Type 2 - complications
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy
by Slavich, Massimo, MD and Maranta, Francesco, MD and Fumero, Andrea, MD and Godino, Cosmo, MD and Giannini, Francesco, MD and Oppizzi, Michele, MD and Colombo, Antonio, MD and Fragasso, Gabriele, MD and Margonato, Alberto, MD
American Journal of Cardiology, The, ISSN 0002-9149, 2016, Volume 117, Issue 10, pp. 1558 - 1561
Refractory angina pectoris (RAP) represents a clinical condition characterized by frequent episodes of chest pain despite therapy optimization. According to... 
Cardiovascular | Follow-Up Studies | Ranolazine - therapeutic use | Vasodilator Agents - therapeutic use | Angina Pectoris - physiopathology | Humans | Tomography, Emission-Computed, Single-Photon | Male | Systole | Exercise Test | Time Factors | Sodium Channel Blockers - therapeutic use | Female | Ventricular Function, Left - physiology | Retrospective Studies | Myocardial Ischemia - diagnosis | Trimetazidine - therapeutic use | Echocardiography | Ventricular Function, Left - drug effects | Stroke Volume - physiology | Angina Pectoris - drug therapy | Myocardial Ischemia - prevention & control | Stroke Volume - drug effects | Cardiovascular Agents - therapeutic use | Angina Pectoris - complications | Myocardial Ischemia - etiology | Benzazepines - therapeutic use | Aged | Myocardial ischemia | Care and treatment | Nitrates | Angina pectoris | Cardiology | Cardiac patients | Medical research | Medicine, Experimental | Research institutes | Studies | Heart attacks | Ischemia | Preservation | Rodents | Coronary vessels | Cardiovascular disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis
by Danchin, Nicolas and Marzilli, Mario and Parkhomenko, Alexander and Ribeiro, Jorge P
Cardiology, ISSN 0008-6312, 12/2011, Volume 120, Issue 2, pp. 59 - 72
Aims: To compare the antianginal efficacy of trimetazidine with that of other agents with no influence on heart rate. Methods and Results: Medline and Embase... 
Review | Angina pectoris | Trimetazidine | Exercise testing | Meta-analysis | MIXED TREATMENT COMPARISONS | CARDIAC & CARDIOVASCULAR SYSTEMS | METABOLISM | DOUBLE-BLIND | COMBINATION | ISOSORBIDE | CORONARY-ARTERY-DISEASE | Single-Blind Method | Trimetazidine - therapeutic use | Double-Blind Method | Vasodilator Agents - therapeutic use | Humans | Treatment Outcome | Exercise Tolerance - drug effects | Randomized Controlled Trials as Topic | Cross-Over Studies | Multicenter Studies as Topic | Angina, Stable - drug therapy | Delayed-Action Preparations | Drug Combinations | Clinical trials | Exercise | Drug therapy | Testing
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Cardiac metabolism as a target for the treatment of heart failure
by Taegtmeyer, Heinrich
Circulation, ISSN 0009-7322, 08/2004, Volume 110, Issue 8, pp. 894 - 896
Enzymes | Editorials | Metabolism | Cardiomyopathy | Insulin | ADENYL CYCLASE | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | GLUCOSE-OXIDATION | ANGINA | RANOLAZINE | PERIPHERAL VASCULAR DISEASE | RAT-HEART | ENERGY-METABOLISM | TRIMETAZIDINE | GLUCAGON | Recombinant Proteins - therapeutic use | Glucagon-Like Peptide 1 | Humans | Peptide Fragments - pharmacology | Ranolazine | Peptide Fragments - physiology | Epoxy Compounds - pharmacology | Protein Precursors - physiology | Myocardium - metabolism | Acetanilides | Fatty Acids - metabolism | Epoxy Compounds - therapeutic use | Glucagon - physiology | Insulin Resistance | Heart Failure - metabolism | Piperazines - therapeutic use | Forecasting | Glucagon - pharmacology | Heart Failure - drug therapy | Protein Precursors - pharmacology | Animals | Dogs | Glucose - metabolism | Protein Precursors - therapeutic use | Glucagon - therapeutic use | Peptide Fragments - therapeutic use | Energy Metabolism - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Modulation of myocardial metabolism: an emerging therapeutic principle
by Horowitz, John D and Chirkov, Yuliy Y and Kennedy, Jennifer A and Sverdlov, Aaron L
Current Opinion in Cardiology, ISSN 0268-4705, 07/2010, Volume 25, Issue 4, pp. 329 - 334
PURPOSE OF REVIEWWe focus on the molecular and cellular basis of the improvement in myocardial energetics, which might represent an attractive therapeutic... 
myocardial metabolism | trimetazidine | myocardial energetics | perhexiline | CARDIAC & CARDIOVASCULAR SYSTEMS | LIPID-METABOLISM | PERHEXILINE-MALEATE | ISCHEMIC-HEART-DISEASE | RANDOMIZED CONTROLLED-TRIAL | FAILURE | STABLE CORONARY-DISEASE | INFARCTION | FATTY-ACID | RAT-HEART | EFFICIENCY | Myocardial Ischemia - metabolism | Trimetazidine - therapeutic use | Vasodilator Agents - therapeutic use | Humans | Hypertrophy, Left Ventricular - metabolism | Myocardium - pathology | Heart Failure - metabolism | Piperazines - therapeutic use | Heart Failure - pathology | Myocardial Ischemia - pathology | Myocardial Perfusion Imaging | Myocardium - cytology | Ranolazine | Cardiovascular Agents - therapeutic use | Amiodarone - therapeutic use | Myocardial Reperfusion | Hypertrophy, Left Ventricular - pathology | Myocardium - metabolism | Acetanilides - therapeutic use | Perhexiline - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Addition of adenosine monophosphate‐activated protein kinase activators to University of Wisconsin solution: A way of protecting rat steatotic livers
by Ben Mosbah, Ismail and Massip‐Salcedo, Marta and Fernández‐Monteiro, Izabel and Xaus, Carme and Bartrons, Ramon and Boillot, Olivier and Roselló‐Catafau, Joan and Peralta, Carmen
Liver Transplantation, ISSN 1527-6465, 03/2007, Volume 13, Issue 3, pp. 410 - 425
This study investigates how the addition of trimetazidine (TMZ) and aminoimidazole‐4‐carboxamide ribonucleoside (AICAR) to University of Wisconsin (UW)... 
SURGERY | NITRIC-OXIDE SYNTHASE | COLD PRESERVATION | TRANSPLANTATION | ISCHEMIA-REPERFUSION INJURY | HEAT-SHOCK PROTEINS | MITOCHONDRIAL PERMEABILITY TRANSITION | EXTENDED PRESERVATION | PRIMARY NONFUNCTION | BILE-DUCT LIGATION | FATTY LIVER | HEME OXYGENASE-1 | GASTROENTEROLOGY & HEPATOLOGY | Liver - enzymology | Enzyme Activators - therapeutic use | Oxidative Stress - physiology | AMP-Activated Protein Kinases | Vascular Resistance - physiology | Mitochondria, Liver - physiology | Adenosine - therapeutic use | Glutathione - therapeutic use | Trimetazidine - therapeutic use | Protein-Serine-Threonine Kinases - physiology | Aminoimidazole Carboxamide - therapeutic use | Fatty Liver - prevention & control | Organ Preservation Solutions - therapeutic use | Rats | Nitric Oxide - physiology | Rats, Zucker | Allopurinol - therapeutic use | Ribonucleotides - therapeutic use | Animals | Reperfusion Injury - prevention & control | Aminoimidazole Carboxamide - analogs & derivatives | Adenine Nucleotides - metabolism | Multienzyme Complexes - physiology | Liver - physiology | Raffinose - therapeutic use | Nitric Oxide Synthase - metabolism | Insulin - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway
by Liu, Zhenling and Chen, Ji-Mei and Huang, Huanlei and Kuznicki, Michelle and Zheng, Shaoyi and Sun, Wanqing and Quan, Nanhu and Wang, Lin and Yang, Hui and Guo, Hui-Ming and Li, Ji and Zhuang, Jian and Zhu, Ping
Metabolism, ISSN 0026-0495, 2015, Volume 65, Issue 3, pp. 122 - 130
Abstract Introduction Trimetazidine (TMZ) is an anti-anginal drug that has been widely used in Europe and Asia. The TMZ can optimize energy metabolism via... 
Endocrinology & Metabolism | Cardioprotection | AMPK signaling | Trimetazidine | Ischemia/reperfusion | MAPK signaling | GLOBAL BURDEN | STABLE ANGINA | PROTEIN-KINASE | CARDIAC ENERGY-METABOLISM | ISCHEMIC-HEART-DISEASE | TUMOR-NECROSIS-FACTOR | CARDIOMYOCYTE APOPTOSIS | FATTY-ACID OXIDATION | COMBINATION TREATMENT | ENDOCRINOLOGY & METABOLISM | BINDING-SITES | Trimetazidine - therapeutic use | Oxidation-Reduction | Vasodilator Agents - therapeutic use | Mice, Inbred C57BL | Myocardial Contraction - drug effects | Male | Myocardium - pathology | Myocardial Infarction - metabolism | AMP-Activated Protein Kinases - drug effects | Myocardial Reperfusion Injury - pathology | Animals | MAP Kinase Signaling System - drug effects | Myocytes, Cardiac - drug effects | Myocardial Infarction - pathology | Myocardium - metabolism | Glucose - metabolism | Mice | Coronary Circulation - drug effects | Myocardial Reperfusion Injury - drug therapy | Fatty Acids - metabolism | Fatty acids | Dextrose | Glucose | Ischemia | reperfusion
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights